脑循环系统治疗仪辅助治疗偏执型精神分裂症的疗效与安全性研究  

Efficacy and safety of cerebral circulatory system therapy device in the auxiliary treatment of paranoid schizophrenia

作　　者：张艳 高咏莉 邱松伟 ZHANG Yan;GAO Yong-li;QIU Song-wei(WardⅧ,the Eighth People's Hospital of Zhengzhou,Zhengzhou 450000,Henan,CHINA;Department of Emergency,the Eighth People's Hospital of Zhengzhou,Zhengzhou 450000,Henan,CHINA)

机构地区：[1]郑州市第八人民医院七病区,河南郑州450000 [2]郑州市第八人民医院急诊科,河南郑州450000

出　　处：《海南医学》2025年第3期337-342,共6页Hainan Medical Journal

基　　金：河南省医学科技攻关计划联合共建项目(编号:LHGJ20210756)。

摘　　要：目的探讨脑循环系统治疗仪辅助治疗偏执型精神分裂症(PSZ)患者的临床效果和安全性。方法前瞻性选取2022年2月至2024年3月郑州市第八人民医院收治的136例PSZ患者纳入研究,按随机数表法分为对照组和研究组各68例。对照组患者给予鲁拉西酮片治疗,研究组患者在对照组治疗的基础上给予脑循环系统治疗仪治疗,均治疗6周。比较两组患者的临床疗效及治疗前、治疗6周后(治疗后)的临床症状[阳性与阴性症状量表(PANSS)评分]、炎症因子[白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)、IL-6)]、氧化应激指标[过氧化氢酶(CAT)、丙二醛(MDA)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)]、神经因子[胶质纤维酸性蛋白(GFAP)、星形胶质源性蛋白(S100β)、脑源性神经营养因子(BDNF)]、认知功能[认知功能成套测试(MCCB)]、社会功能[个体与社会功能量表(PSP)]、生活质量[精神分裂症生活质量量表(SQLS)]和生活满意度[生活满意度量表(SWLS)],同时比较两组患者治疗期间的不良反应发生情况。结果研究组患者的治疗总有效率为77.94%,明显高于对照组的61.76%,差异有统计学意义(P<0.05);治疗后,研究组患者PANSS量表中的阴性症状、一般精神病理症状、阳性症状评分及总分分别为(14.76±2.12)分、(19.87±1.02)分、(15.36±1.42)分、(49.99±4.52)分,明显低于对照组的(18.59±2.68)分、(23.35±1.36)分、(19.33±1.87)分、(61.27±6.81)分,差异均有统计学意义(P<0.05);治疗后,研究组患者的IL-1β、TNF-α、IL-6、MDA分别为(30.25±3.26)ng/L、(9.33±2.03)ng/L、(3.86±0.46)ng/L、(1.95±0.51)nmol/L,明显低于对照组的(35.87±4.11)ng/L、(13.35±3.17)ng/L、(4.77±0.41)ng/L、(2.87±1.03)nmol/L,SOD、CAT、GSH-Px分别为(26.38±5.32)U/mL、(9.37±2.12)U/mL、(90.35±6.12)U/mL,明显高于对照组的(22.41±4.63)U/mL、(7.93±1.85)U/mL、(83.64±5.58)U/mL,差异均有统计学意义(P<0.05);治疗后,研�Objective To investigate the effect of cerebral circulatory system therapy device in the auxiliary treatment of patients with aranoid schizophrenia(PSZ).Methods A total of 136 patients with PSZ admitted to the Eighth People's Hospital of Zhengzhou from February 2022 to March 2024 were included in the study.The patients were divided into a control group and a study group according to the random number table,with 68 cases in each group.Patients in the control group were treated with Lurasidone tablets,while those in the study group were treated with a cerebral circulation system therapy device on the basis of the control group's treatment.The treatment lasted for 6 weeks.The clinical efficacy and adverse reactions of the two groups were compared,as well as the changes in clinical symptoms(Positive and Negative Syndrome Scale[PANSS]scores),inflammatory factors(interleukin-1β[IL-1β],tumor necrosis factor-α[TNF-α],IL-6),oxidative stress indicators(catalase[CAT],malondialdehyde[MDA],superoxide dismutase[SOD],glutathione peroxidase[GSH-Px]),neurotrophic factors(glial fibrillary acidic protein[GFAP],S100 calcium binding protein[S100β]),brain-derived neurotrophic factor[BDNF]),cognitive function(MATRICS Consensus Cognitive Battery[MCCB]),social function(Personal and Social Performance Scale[PSP]),quality of life(Schizophrenia Quality of Life Scale[SQLS]),and Satisfaction with Life Scale(SWLS)before treatment and at 6 weeks after treatment.Results The total effective rate of the study group was 77.94%,which was significantly higher than the control group’s 61.76%(P<0.05).After treatment,the negative symptom,general psychopathological symptom,positive symptom score,and total score of PANSS in the study group were(14.76±2.12)points,(19.87±1.02)points,(15.36±1.42)points,and(49.99±4.52)points,respectively,which were significantly lower than(18.59±2.68)points,(23.35±1.36)points,(19.33±1.87)points,and(61.27±6.81)points in the control group(P<0.05).After treatment,the levels of IL-1β,TNF-α,IL-6,and MDA in the stu

关 键 词：偏执型精神分裂症 鲁拉西酮片 脑循环系统治疗仪 认知功能 炎症因子 安全性 

分 类 号：R749.3[医药卫生—神经病学与精神病学]